Markov model into the cost‐utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis

OBJECTIVE: To estimate the incremental cost‐utility of etanercept and infliximab compared with usual care in active ankylosing spondylitis. METHODS: A Markov model over five years with cycle times of three months was computed. Patients included all had active disease, defined as Bath ankylosing spon...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Boonen, A, van der Heijde, D, Severens, J L, Boendermaker, A, Landewé, R, Braun, J, Brandt, J, Sieper, J, van der Linden, Sj
Format: Artigo
Jezik:Inglês
Izdano: BMJ Group 2006
Teme:
Extended Report
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1798006/
https://ncbi.nlm.nih.gov/pubmed/16014677
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2004.032565
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items